Table 3.
Main effect of multivariate analysis.
| N | HR | 95% CI Lower Limit | 95% CI Upper Limit | p-value | |
|---|---|---|---|---|---|
| Grade 3–4 acute GVHD | |||||
| Conditioning regimen | |||||
| Flu/Bu | 99 | 1 | 0.79 | ||
| Flu/ Mel 140 | 301 | 0.89 | 0.48 | 1.66 | |
| Flu/Cy | 65 | 0.73 | 0.29 | 1.82 | |
| Chronic GVHD | |||||
| Conditioning regimen | |||||
| Flu/Bu | 100 | 1 | 0.12 | ||
| Flu/ Mel 140 | 305 | 0.88 | 0.65 | 1.18 | |
| Flu/Cy | 69 | 0.65 | 0.43 | 0.99 | |
| Chronic GVHD adjusted for significant covariate: ATG/alemtuzumab use in conditioning. | |||||
| Non-relapse mortality (NRM) | |||||
| Conditioning regimen | |||||
| Flu/Bu | 102 | 1 | 0.54 | ||
| Flu/ Mel 140 | 317 | 1.21 | 0.66 | 2.23 | |
| Flu/Cy | 72 | 0.83 | 0.34 | 2.05 | |
| NRM adjusted for significant covariates: patient age and donor type. | |||||
| Progression/relapse | |||||
| Conditioning regimen | |||||
| Flu/Bu | 102 | 1 | 0.02 | ||
| Flu/ Mel 140 | 318 | 0.73 | 0.53 | 1.00 | |
| Flu/Cy | 72 | 1.13 | 0.76 | 1.66 | |
| Progression/relapse adjusted for significant covariate: remission status at HCT. | |||||
| Progression free survival | |||||
| Conditioning regimen | |||||
| Flu/Bu | 102 | 1 | 0.14 | ||
| Flu/ Mel 140 | 318 | 0.82 | 0.62 | 1.08 | |
| Flu/Cy | 72 | 1.06 | 0.75 | 1.51 | |
| Progression free survival adjusted for significant covariate: remission status at HCT. | |||||
| Overall Survival | |||||
| Conditioning regimen ≤ 11*** months | |||||
| Flu/Bu | 102 | 1 | 0.03 | ||
| Flu/ Mel 140 | 318 | 0.80 | 0.49 | 1.32 | 0.39 |
| Flu/Cy | 72 | 0.28 | 0.10 | 0.73 | 0.009 |
| Conditioning regimen > 11 months*** | |||||
| Flu/Bu | 78 | 1 | 0.02 | ||
| Flu/ Mel 140 | 256 | 1.62 | 0.93 | 2.82 | 0.09 |
| Flu/Cy | 64 | 2.46 | 1.32 | 4.61 | 0.005 |
| Overall survival adjusted for significant covariate: remission status at HCT. | |||||
***
The 11-months was chosen as the cut-off OS based on the maximum likelihood value in the Cox model.